Recent Updates
Recently added Catalysts
SKYE Negative Sentiment Score: 25/100

SKYE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Skye Bioscience, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Key Takeaway: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Skye Bioscience, Inc., targeting significant alleged violations of federal securities laws. The lawsuit focuses on misleading statements made by the company's officers regarding its drug nimacimab, which was claimed to be more effective than it is believed to be. Affected investors who acquired Skye securities between November 4, 2024, and October 3, 2025, are encouraged to participate in the lawsuit. Plaintiffs have until January 16, 2026, to request lead plaintiff status.

Market Sentiment Analysis

CONCERNS & RISKS

  • Class action lawsuit filed against Skye Bioscience for alleged securities law violations.
  • Claims that the company's drug nimacimab was less effective than represented.
  • Public statements by defendants during the class period were reportedly false or misleading.
  • Investors are experiencing substantial losses and are encouraged to join the lawsuit.

Full Press Release Details

NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Skye Bioscience, Inc. (“Skye” or “the Company”) (NASDAQ: SKYE) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Skye securities between November 4, 2024 and October 3, 2025, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/SKYE.
The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding Skye’s business, operations, and prospects. Specifically, the Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) nimacimab was less effective than Defendants had led investors to believe; (2) accordingly, nimacimab’s clinical, regulatory, and commercial prospects were overstated; and (3) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/SKYE. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in Skye you have until January 16, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com

Tags

Frequently Asked Questions

What is the class action lawsuit against Skye Bioscience about?

The lawsuit alleges that Skye Bioscience made false statements about its drug nimacimab's effectiveness.

Who can join the class action against Skye Bioscience?

Anyone who purchased Skye securities between November 4, 2024, and October 3, 2025, can join.

Is there a cost to join the class action lawsuit?

No, the firm represents investors on a contingency fee basis, requiring no upfront costs.

When is the deadline to request lead plaintiff status?

The deadline to request lead plaintiff status is January 16, 2026.

How can I contact the firm for more information?

You can contact Peretz Bronstein or Nathan Miller at 332-239-2660 for details.

Last updated: Nov 24, 2025